Health Care & Life Sciences » Biotechnology | Intron Biotechnology Inc.

Intron Biotechnology Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
9,277
9,980
11,835
10,222
10,963
Cost of Goods Sold (COGS) incl. D&A
5,333
4,885
4,575
5,742
6,673
Gross Income
3,944
5,095
7,260
4,481
4,290
SG&A Expense
3,885
3,847
5,129
5,681
5,977
EBIT
59
1,125
2,132
1,200
1,687
Unusual Expense
125
787
247
284
6,351
Non Operating Income/Expense
30
7
79
99
176
Interest Expense
254
682
468
96
136
Pretax Income
56
118
1,562
710
8,130
Income Tax
298
139
4
99
218
Consolidated Net Income
354
21
1,558
610
8,348
Net Income
354
21
1,558
610
8,348
Net Income After Extraordinaries
354
21
1,558
610
8,348
Net Income Available to Common
354
21
1,558
610
8,348
EPS (Basic)
26.00
1.00
107.00
40.00
542.00
Basic Shares Outstanding
13
14
15
15
15
EPS (Diluted)
26.31
1.47
107.00
39.65
542.32
Diluted Shares Outstanding
13
14
15
15
15
EBITDA
1,094
1,936
3,104
53
311
Other Operating Expense
-
123
-
-
-
Non-Operating Interest Income
155
232
224
204
220
Minority Interest Expense
-
-
-
-
1

About Intron Biotechnology

View Profile
Address
Unit 701-704, Joong-Ang Induspia
Seongnam-si GY 13202
Korea, Republic Of
Employees -
Website http://www.intron.co.kr
Updated 09/14/2018
iNtRON Biotechnology, Inc. engages in the development of super-bacteria treatment, antibiotics alternatives, bio new drug, molecular diagnostics and artificial blood. Its products include anti-bacterial agents, identification kits, research reagents and kits. The company was founded on January 18, 1999 and is headquartered in Seongnam-si, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.